Deerfield Contributes Insights to Peer-Reviewed Study on Access to Life-Saving Drug, Buprenorphine, Examining Growth and Distribution of Waivered Providers

Despite Evidence Showing the Opioid Crisis Disproportionately Affects Rural Areas, Prescriber Growth There Remains Considerably Slower

Despite Evidence Showing the Opioid Crisis Disproportionately Affects Rural Areas, Prescriber Growth There Remains Considerably Slower 

While there has been an uptick in the number of U.S. clinicians having waivers to prescribe the potentially life-saving drug, buprenorphine, the total number of waivered prescribers in 2017 still represented fewer than 10 percent of all primary care providers, found a report published online in the January 7 issue of the Annals of Internal Medicine.

Moreover, although rural communities have been shown to be disproportionately affected by the opioid epidemic, the growth in the number of providers having this required certification there remains strikingly low, compared to more urban areas. Authors from the RAND Corporation suggest a need for more targeted efforts to increase access to the medication.

To assess the growth in buprenorphine-waivered providers by region and demographics, the investigators leveraged insights from analysis performed by the Deerfield Institute.

Tapping population estimates from the 2010 U.S. census and total physicians per capita, the researchers calculated the total number of waivered providers per 100,000 from 2007 to 2017. Statistics from the Census Bureau were also used to determine per-capita sociodemographic characteristics.

Over the decade studied, the researchers found that the number of waivered providers, in general, increased from 3.80 to 17.29 per 100,000 persons. Growth rate of waivered providers was markedly slower in small, nonmetropolitan areas, as it was in communities with lower levels of education.

The Food and Drug Administration approved buprenorphine for treating opioid dependency in 2002. According to Kaiser Health News, once physicians secure the waiver, they can prescribe buprenorphine in a range of settings, including primary care offices, community hospitals and correctional facilities. Compared with methadone, Buprenorphine is less likely to result in fatal overdoses.

The federal government is undertaking a number of efforts to increase the amount of buprenorphine prescribers.

More details on the research may be found here: Annals of Internal Medicine.

The authors of the paper are Ryan K. McBain, PhD, MPH, Andrew Dick, PhD of the RAND Corporation in Boston, Massachusetts and Mark Sorbero, MS, and Bradley D. Stein, MD, PhD of the RAND Corporation in Pittsburgh, Pennsylvania.

American Addiction Centers

AAC Holdings or American Addiction Centers is a leading provider of inpatient substance abuse treatment services which operates 18 substance abuse treatment facilities and one mental health facility specializing in binge eating disorders. Located throughout the United States, these facilities are focused on delivering researched-based effective clinical care and treatment solutions.

Deerfield Makes $50 Million Commitment to AAC Holdings to Expand Clinical Care and Treatment with Additional $50 Million Incremental Facility

New York, New York – October 5, 2015 – Deerfield announced today that it has made a commitment of up to $50 million to AAC Holdings, Inc.to expand its efforts to deliver research-based clinical care and treatment for individuals with drug and alcohol addictions. In addition, Deerfield has agreed to provide up to an additional $50 million under certain circumstances. 

The $50 million of capital commitment consists of $25 million of subordinated convertible debt and up to $25 million of subordinated debt. AAC drew down $25 million of subordinated convertible debt at closing. The $25 million of unsecured subordinated debt can be drawn for acquisition financing through September 30, 2016 in minimum $5 million increments and can be repaid under certain conditions without penalty prior to October 2, 2017. In addition to the $25 million of subordinated convertible debt drawn at closing, there is an incremental subordinated debt facility that may be drawn, subject to certain conditions, up to an additional $50 million. 

These facilities will enable AAC to further expand its presence as a leading provider of inpatient substance abuse treatment services for individuals with drug and alcohol addictions. AAC was created to facilitate research-based treatment programs with structured curricula for detoxification, residential treatment, partial hospitalization and intensive outpatient care.

“We are excited to have Deerfield work with us as our partner in expanding the business. Deerfield has proven to be creative in its approach to providing us with the capital needed to enhance our platform and add additional services to address a substance abuse epidemic that is consuming our country,” said Michael Cartwright, Chairman and Chief Executive Officer of AAC.

About AAC

American Addiction Centers is a leading provider of inpatient substance abuse treatment services. We treat adults as well as adolescents who are struggling with drug addiction, alcohol addiction, and co-occurring mental/behavioral health issues.We operate 18 substance abuse treatment facilities and one mental health facility specializing in binge eating disorders. Located throughout the United States, these facilities are focused on delivering effective clinical care and treatment solutions. For more information, please find us at AmericanAddictionCenters.org or follow us on Twitter at @AAC_Tweet

About Deerfield

Deerfield is an investment management firm committed to advancing healthcare through investment, information and philanthropy.

For more information, please visit www.deerfield.com.

Contacts

Deerfield Management Company
Karen Heidelberger, 212-692-7140
[email protected]